Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850971 | 0.87 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6851008 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL29408738 | 0.83 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL1430533 | 0.83 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL440095 | 0.82 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL29179553 | 0.80 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL16980390 | 0.79 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12683328 | 0.79 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL30851501 | 0.79 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL11202950 | 0.79 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216385-A1 | Triazole derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1293503-A1 | TRIAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216385-A1 | Triazole derivatives | SLC18A3, SLC18A2, SLC6A3 | RAB9A 1845/4885NPC1 262/4885SMN1; SMN2 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.